The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.

@article{RussellJones2010TheSA,
  title={The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.},
  author={David Russell-Jones},
  journal={International journal of clinical practice},
  year={2010},
  volume={64 10},
  pages={1402-14}
}
Established therapies for type-2 diabetes effectively reduce blood glucose, but are often associated with adverse effects that pose risks to patient's health or diminish adherence to treatment. Weight gain, hypoglycaemia and gastrointestinal symptoms are commonly reported and some agents may not be safe for use in patients with renal impairment or elevated cardiovascular risk. New treatments based on the action of the endogenous human hormone glucagon-like peptide-1 (GLP-1), including exenatide… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Exenatide Extended-Release

Drugs • 2012
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…